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Research
Polybrominated diphenyl ethers (PBDEs) 
are widely used as flame retardants in poly­
urethane foams, textiles, and electric appli­
ances. The annual global sales of PBDEs 
were around 67,100 metric tons in 1999 and 
67,400 metric tons in 2001 (Bromine Science 
and Environmental Forum 2006). Because 
PBDEs are very stable and are not chemically 
bonded to the material in which they are 
used, they are widely found in the environ­
ment and have also been found in human tis­
sue (Hites 2004; Law et al. 2006). In human 
tissue, the tetra­, penta­, and hexabrominated 
congeners, especially BDEs 47, 99, 100, 153, 
and 154, were more predominant than the 
more highly brominated congeners, such as 
BDE­209 (Hites 2004). As a result of their 
environmental ubiquity, two commercial 
PBDE products, containing tetra­ through 
octabrominated congeners, have been banned 
by the European Union and by several U.S. 
states, and the major manufacturer of these 
two products in the United States stopped 
producing them in 2004 (Renner 2004).
The prevalence of PBDEs in human tis­
sue is of concern because of their potential 
toxicity; these effects include carcinogenicity, 
neuro  toxicity, reproductive toxicity, and thy­
roid toxicity (Darnerud et al. 2001). Although 
the toxicity of PBDEs is not fully under­
stood, some of the toxic effects might be due 
to their hydroxylated metabolites, especially 
the hydroxylated PBDEs (HO­PBDEs). For 
instance, levels of serum thyroxine (T4, a thy­
roid hormone and the precursor of active thy­
ronine, T3) were significantly decreased when 
rats were exposed to PBDEs (Darnerud et al. 
2007; Stoker et al. 2004; Zhou et al. 2002). 
The effect of PBDEs on T4 levels may require 
metabolic activation because HO­PBDEs, but 
not the PBDE congeners themselves, behave 
as ligands for human transthyretin (TTR; a 
major thyroid hormone transport protein) 
in vitro (Meerts et al. 2000). In addition, 
Hamers et al. (2008) reported that the trans­
thyretin­binding potencies of HO­PBDEs 
were orders of magnitude higher than that 
of BDE­47. Similarly, PBDE has mild estro­
genic effects in mice (Mercado­Feliciano and 
Bigsby 2008a), and these effects are likely 
caused by HO­PBDEs that act as ligands for 
the estrogen receptor (Mercado­Feliciano and 
Bigsby 2008b). In addition, HO­PBDEs were 
shown to inhibit estradiol­sulfotransferase 
(Hamers et al. 2008) and placental aromatase 
(Cantón et al. 2008).
HO­PBDEs have been identified in blood 
samples from rats and mice after exposure to 
PBDE mixtures (Malmberg et al. 2005; Qiu 
et al. 2007) and observed in blood samples 
from wild animals such as fishes, birds, and 
mammals (Marsh et al. 2004; Valters et al. 
2005; Verreault et al. 2005). However, with 
one exception, there have been no reports 
about PBDE metabolites in human blood. 
The exception was a report about HO­PBDEs 
in pooled human blood samples taken from 
children living or working at a municipal 
waste disposal site in Managua, Nicaragua 
(Athanasiadou et al. 2008). To study the 
metabolism of PBDEs in humans, we have 
identified and quantitated the hydroxylated 
metabolites of PBDEs, including HO­PBDEs 
and bromophenols, in 20 individual human 
blood samples from pregnant women and 
newborn babies from the United States. 
HO­PBDEs and bromophenols were both 
found to be important metabolites of PBDEs 
in plasma after mice were exposed to a com­
mercial PBDE mixture (Qiu et al. 2007). 
Here we report these HO­PBDE concentra­
tions and compare these levels to those meas­
ured in mouse blood after exposure to high 
levels of DE­71, a commercial penta­BDE 
mixture (Qiu et al. 2007).
Materials and Methods
Chemicals. 4´­HO­BDE­17, 2´­HO­BDE­28, 
4­HO­BDE­42,  3­HO­BDE­47, 
5­HO­BDE­47,  6­HO­BDE­47, 
4´­HO­BDE­49, 2´­HO­BDE­66, and 
2´­HO­BDE­68 were gifts from Göran Marsh 
(Stockholm University, Stockholm, Sweden) 
and were synthesized as described elsewhere 
(Marsh et al. 2004). 4­MeO­BDE­90, 
6´­MeO­BDE­99, and 2,4,6­tribromophe­
nol were from AccuStandard (New Haven, 
CT). 5´­MeO­BDE­99, 5´­MeO­BDE­100, 
4´­MeO­BDE­101, 4´­MeO­BDE­103, and 
4­HO­13C12­PCB­187 were from Wellington 
Laboratories (Guelph, ON, Canada). 
2,4­Dibromophenol and 2,4,5­tribromo  phenol 
were from Cambridge Isotope Laboratories 
(Cambridge, MA). All the PBDE congeners 
(BDE­28, 47, 71, 77, 99, 100, 153, 154, and 
166) were purchased from AccuStandard. 
The full names of these   compounds are 
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Ba c k g r o u n d : A previous study from our laboratory showed that polybrominated diphenyl ethers 
(PBDEs) were metabolized to hydroxylated PBDEs (HO-PBDEs) in mice and that para-HO-
PBDEs were the most abundant and, potentially, the most toxic metabolites.
oB j e c t i v e : The goal of this study was to determine the concentrations of HO-PBDEs in blood 
from pregnant women, who had not been intentionally or occupationally exposed to these flame 
retardants, and from their newborn babies.
Me t h o d s : Twenty human blood samples were obtained from a hospital in Indianapolis, Indiana, 
and analyzed for both PBDEs and HO-PBDEs using electron-capture negative-ionization gas 
chromatographic mass spectrometry.
re s u l t s : The metabolite pattern of HO-PBDEs in human blood was quite different from that 
found in mice; 5-HO-BDE-47 and 6-HO-BDE-47 were the most abundant metabolites of 
BDE-47, and 5´-HO-BDE-99 and 6´-HO-BDE-99 were the most abundant metabolites of 
BDE-99. The relative concentrations between precursor and corresponding metabolites indicated 
that BDE-99 was more likely to be metabolized than BDE-47 and BDE-100. In addition, three 
bromophenols were also detected as products of the cleavage of the diphenyl ether bond. The ratio 
of total hydroxylated metabolites relative to their PBDE precursors ranged from 0.10 to 2.8, indi-
cating that hydroxylated metabolites of PBDEs were accumulated in human blood.
co n c l u s i o n s : The quite different PBDE metabolite pattern observed in humans versus mice indicates 
that different enzymes might be involved in the metabolic process. Although the levels of HO-PBDE 
metabolites found in human blood were low, these metabolites seemed to be accumulating.
ke y w o r d s : bromophenols, flame retardants, HO-PBDEs, human blood, metabolites, PBDEs, 
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listed in the Supplemental Material (avail­
able online at http://www.ehponline.org/
members/2008/11660/suppl.pdf).
All the phenolic compounds were methy­
lated with fresh diazomethane, which was 
prepared from Diazald (Sigma Chemical Co., 
St. Louis, MO) (Black 1983). All the organic 
solvents and water used for the extraction and 
cleanup procedures were residue­analysis grade.
Sample collection. Human studies were 
performed in accordance with the guidelines 
and approval of the Institutional Review Board 
at Indiana University School of Medicine. 
Pregnant women were enrolled in the study 
during 2003–2004 at Wishard Memorial 
County Hospital (Indianapolis, IN). Random 
fetal blood samples (n = 16) were collected 
from the umbilical cord vein by syringe after 
delivery; these samples were not accompanied 
by any clinical data or other information about 
the pregnant women. Upon consent to enter 
the study, four women were administered a 
questionnaire to determine potential sources 
of contamination; none of the subjects had 
any identifiable source of occupational expo­
sure to PBDE. Maternal blood was obtained 
upon admission to the maternity ward; in 
this study, only one of the four maternal sam­
ples was matched with a fetal sample. Blood 
samples were collected in heparinized tubes, 
maintained at 4°C, and centrifuged at 800 × g 
for 15 min to allow collection of the plasma 
fraction. All the plasma samples were kept at 
–20°C until extraction.
Sample extraction and preparation. 
We slightly modified previous methods 
(Hovander et al. 2000; Qiu et al. 2007) for 
this study. Twenty samples (from 4.2 g to 
13.8 g, with an average wet weight of 8.9 g) 
were analyzed. Before extraction, each sample 
was transferred to a clean centrifuge tube and 
spiked with a known amount of BDE­77 and 
4­HO­13C12­PCB­187 as recovery surrogate 
standards. Hydrochloric acid (1 mL, 6 M) 
and 2­propanol (6 mL) were added; the sam­
ple was vortexed after each addition. After 
denaturizing the samples, they were extracted 
three times, each time with 6 mL of a hexane/
methyl tert­butyl ether mixture (1:1 by vol­
ume). The organic extracts were combined, 
and approximately 20% of the solution was 
removed for gravimetric determination of 
lipid mass. The rest of each sample was blown 
down to 2 mL with clean nitrogen, and 2 mL 
of potassium hydroxide (0.5 M in 50% etha­
nol) was added to ionize the phenolic ana­
lytes. After extraction with hexane three times 
to separate the PBDEs, the aqueous phase 
was acidified with hydrochloric acid (2.1 mL, 
0.5 M), then the phenolic compounds were 
extracted three times with a hexane/methyl 
tert­butyl ether mixture (9:1 by volume).
The neutral fraction was treated with 
5 mL of concentrated sulfuric acid twice to 
remove lipids, followed by alumina column 
chromatography (6 cm × 0.6 cm i.d., with 
0.5 cm anhydrous sodium sulfate on the 
top). The column was eluted with 8 mL of 
hexane, followed by 8 mL of a hexane/dichlo­
romethane mixture (3:2 by volume). The 
PBDE congeners were in the second fraction. 
BDE­71 was added as an internal standard, 
and the samples were blown down to approx­
imately100 µL before gas chromatographic 
mass spectrometry (GC/MS) analysis.
We concentrated the phenolic fraction by 
nitrogen blow­down, and the residual water 
was removed with an anhydrous sodium sul­
fate column (5 cm × 0.6 cm i.d.). To meth­
ylate the phenolic analytes, samples were 
treated with diazomethane at room tempera­
ture overnight. After methylation, the samples 
were treated with concentrated sulfuric acid 
three times to remove lipid, followed by alu­
mina column chromatography, which was 
the same as that used for the neutral fraction. 
Finally, BDE­166 was added as the internal 
standard, and samples were blown down to 
approximately 50 µL for GC/MS analysis. To 
prevent potential photo­degradation, during 
the whole process the centrifuge tubes were 
wrapped with aluminum foil, or amber vials 
were used.
Instrumental analysis. We analyzed both 
neutral and methylated phenolic fractions 
by GC/MS (Agilent 6890/5973) with an 
electron­capture­negative ionization (ECNI) 
ion source. We used selected ion moni­
toring of m/z 79 and 81 for quantitation. 
The GC injection port was held at 285°C, 
with an injection volume of 2 µL. A non­
polar Rxi­5ms column (15 m length; 250 µm 
i.d.; 0.25 µm film thickness; Restek Corp., 
Bellefonte, PA) was used to separate both 
the neutral and methylated phenolic ana­
lytes. The GC oven temperature program 
was as follows: held at 60°C for 1 min; 10°C/
min to 240°C; 25°C/min to 325°C; held 
for 8 min. The same instrument, but with a 
polar SP­2331 column (30 m length; 250 µm 
i.d.; 0.20 µm film thickness; Supelco Inc., 
Bellefonte, PA), was used for the confirma­
tion of the methylated phenolic analytes. In 
this case, the GC temperature program was 
as follows: held at 80°C for 1 min; 10°C/min 
to 260°C; held for 16 min. Method detection 
limits were 0.5–2 pg/g plasma.
Quality control. Several quality con­
trol criteria were used to ensure the correct 
identification and quantitation of the target 
compounds. First, the GC retention times 
matched those of the standard compounds 
within ± 0.1 min. Second, the signal­to­noise 
ratio was greater than 5:1. Third, the isoto­
pic ratios for bromine ion pairs were within 
± 15% of the theoretical values. In addition 
to the 20 blood samples, we also prepared 
11 blank samples with pure water (~ 10 mL) 
as the blank matrix. Only 2,4­DBP (dibromo­
phenol), 2,4,6­TBP (tribromo  phenol), 
BDE­47, and BDE­99 were detected in the 
blank samples, and the blank values were 
around 9%, 7%, 2%, and 9% of the average 
concentration values measured in the blood 
samples, respectively. The recoveries (mean ± 
SE) of the surrogate standards were 99 ± 3 % 
for BDE­77, and 90 ± 6 % for 4­HO­13C12­
PCB­187, respectively. In this article, the data 
were not blank or recovery corrected.
Results
We measured PBDE congeners 28, 47, 99, 
100, 153, and 154, which were the most 
abundant PBDE congeners observed in 
human blood in most other studies (Hites 
2004). The mean and median concentrations 
of these six congeners ranged from 2.3 to 
70 ng/g and from 0.8 to 13 ng/g lipid, respec­
tively, in the fetal samples and from 0.5 to 17 
ng/g and 0.3 to 15 ng/g lipid, respectively, 
in the maternal samples [Table 1; the full 
data set is given in the Supplemental Material 
(available online at http://www.ehponline.
org/members/2008/11660/suppl.pdf)]. 
Among these congeners, BDE­28, 47, 99, 
and 100 were detected in all 20 samples, 
BDE­153 was detected in 19 samples, and 
BDE­154 was detected in 17 samples. No 
methoxylated PBDEs (MeO­PBDEs) were 
detected in the neutral clean­up fraction.
We also measured the concentrations of 
18 potential phenolic metabolites, includ­
ing 3 bromophenols and 15 hydroxylated 
PBDEs [see Supplemental Material (avail­
able online at http://www.ehponline.org/
members/2008/11660/suppl.pdf) for 
the structures of these HO­PBDEs]. The 
3 bromo  phenols were detected in all samples, 
and 7 of the 15 HO­PBDEs were identified 
and quantitated in all or some of the samples. 
The concentrations of these hydroxylated 
metabolites and their percent of the total 
phenolic compounds are shown in Table 1.
Discussion
PBDEs. Mazdai et al. (2003) reported that the 
concentrations of PBDEs in fetal blood did not 
differ from those in the corresponding mater­
nal blood, and, based on analysis of unpaired 
maternal and fetal samples, our study con­
firms this finding [see Supplemental Material 
(available online at http://www.ehponline.
org/members/2008/  11660/suppl.pdf) for 
a statistical analysis comparing the fetal and 
maternal concentrations]. In the present study 
there was only one set of paired maternal–
fetal samples; therefore, we could not directly 
determine if the HO­PBDE blood levels corre­
lated between mother and baby. The fetal liver 
and adrenal glands express type I and type II 
enzymes capable of metabolizing xeno  biotics 
that cross the placenta (Syme et al. 2004). 
Qiu et al.Metabolites of polybrominated diphenyl ethers in human blood
Environmental Health Perspectives  •  v o l u m e  117 | n u m b e r  1 | January 2009  95
Furthermore, the placenta expresses type I 
enzymes, and these are inducible by xenobiot­
ics, such as those in cigarette smoke (Hakkola 
et al. 1998). Thus, the question of whether the 
fetus is at greater or lesser risk of exposure to 
PBDE metabolites requires further study.
In this study, the total concentrations of 
the 6 PBDE congeners in these 20 samples 
ranged from 4.7 to 800 ng/g lipid, with an 
average of 100 and a median of 31 ng/g lipid 
(Table 1). These values are close to previously 
reported PBDE concentrations in human 
blood from Indiana, where the concentra­
tions ranged from 14 to 580 ng/g lipid (n = 
24; Mazdai et al. 2003), and they are close 
to concentrations measured in fetal blood 
from Baltimore, Maryland (from not detected 
to 310 ng/g lipid for BDE­47, n = 297; 
Herbstman et al. 2007). All the concentrations 
reported here were much higher than those 
reported for human blood from Europe (e.g., 
1.1–20 ng/g lipid for total PBDEs in 50 serum 
samples from Sweden and not detected to 6.1 
ng/g lipid for BDE­47 in 81 maternal and fetal 
serum samples from the Netherlands) (Meijer 
et al. 2008; Weiss et al. 2006), indicating that 
North Americans are exposed to higher levels 
of PBDEs than are Europeans.
The average profile of the PBDE con­
geners measured in this study is shown in 
Figure 1. For comparison, the congener profile 
of DE­71, an important commercial penta­
BDE mixture and the presumptive source of 
PBDEs in human blood, is also shown.
Figure 1 shows that the percentage of 
BDE­99 in human blood was much lower 
than in DE­71, whereas the percentage of 
BDE­47 and 153 in human blood was higher 
than in DE­71. Neglecting the potential for 
slightly different uptake efficiencies of these 
congeners, these data suggest that, in human 
blood, BDE­99 may be the least persistent 
PBDE congener in DE­71. In fact, although 
BDE­99 is the most abundant congener of 
commercial DE­71, BDE­47 is usually the 
most abundant congener found in human 
blood samples (Hites 2004), and BDE­153 
is sometimes the most abundant congener 
in people from low­exposure regions (Meijer 
et al. 2008; Weiss et al. 2006).
Different metabolic rates among the 
congeners might cause the different conge­
ner profiles observed for DE­71 and human 
blood. As found in this study, BDE­99 was 
more likely to be degraded to HO­PBDEs 
than were BDE­47 and BDE­100. 
Hydroxylated metabolites. In this study, 
hydroxylated metabolites included both 
mono­hydroxylated PBDEs (HO­PBDEs) 
and bromophenols. Of the 18 assessed 
hydroxylated metabolites, 7 HO­PBDEs and 
3 bromophenols were measured in almost all 
of the 20 samples. Typical chromatograms of 
methylated HO­PBDEs on two different GC 
columns are shown in Figure 2.
One might assume that the hydroxylated 
metabolites, being more polar molecules, 
would be excreted more readily than the par­
ent PBDEs, and thus, the concentration of 
these metabolites would be much lower than 
those of PBDEs in blood. This is not what we 
observed. The average total concentration of 
HO­PBDEs and bromophenols was 79 ng/g 
lipid (range, 2.0–900 ng/g lipid). The average 
concentration ratio of hydroxylated metabo­
lites to PBDEs was 0.85 (range, 0.10–2.8), 
indicating that concentration of these metabo­
lites was comparable to or even higher than 
that of PBDEs in these samples. This ratio was 
also much higher than that found in blood 
samples from young people from Managua, 
Nicaragua (Athanasiadou et al. 2008), perhaps 
because some abundant hydroxylated metabo­
lites (5­HO­BDE­47, 6´­HO­BDE­99, and 
bromophenols) were not measured in that 
study. The high concentrations of metabo­
lites and their relatively high ratio to PBDEs 
indicate that the hydroxylated metabolites of 
PBDEs may accumulate in human blood; and 
thus in this paper, we provide the concen­
trations of the hydroxylated metabolites on a 
lipid weight basis.
HO-PBDEs. As discussed above, BDE­47 
is an important congener in the commercial 
penta­BDE product and the most abundant 
PBDE congener found in human blood in 
this and in most other studies (Hites 2004). 
According to the proposed metabolic path­
way for mice (Qiu et al. 2007), there are six 
possible mono­hydroxylated PBDE metabo­
lites of BDE­47, presumably produced by 
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Table 1. Concentrations (ng/g lipid) of PBDE and HO-PBDE congeners in fetal and maternal blood and their percent of total measurable analytes. 
  Fetal samples (n = 16)  Maternal samples (n = 4)  Combined samples ( n = 20)  Mice (n = 15)a
Compound or congener  Mean ± SE  Median  % of total mean  Mean ± SE  Median  % of total mean  Mean ± SE  Median  % of total mean  % of total mean
PBDE congener
  BDE-28  2.3 ± 1.0  0.8  1.9  0.5 ± 0.2  0.3  1.4  1.9 ± 0.8  0.7  1.9  0.2
  BDE-47  70 ± 36  13  59  17 ± 5.1  15  49  60 ± 29  13  58  19
  BDE-99  22 ± 11  5.3  18  6.3 ± 1.9  6.3  18  19 ± 8.6  5.3  18  20
  BDE-100  12 ± 5.5  2.6  9.8  3.0 ± 0.3  3.0  8.7  9.9 ± 4.4  2.6  9.7  6.6
  BDE-153  9.4 ± 4.1  2.7  8.0  6.7 ± 2.5  5.5  20  8.9 ± 3.2  3.8  8.7  54
  BDE-154  4.6 ± 2.4  1.3  3.9  1.2 ± 0.1  1.2  3.6  3.8 ± 1.9  1.2  3.7  1.0
  Total  120 ± 55  31    34 ± 8.5  34    100 ± 45  31
Phenolic metabolite
  2,4-DBP  20 ± 12  4.7  21  1.5 ± 0.5  1.3  21  16 ± 9.6  3.5  21  15
  2,4,5-TBP  7.9 ± 6.0  1.2  8.2  0.2 ± 0.03  0.2  3.6  6.4 ± 4.8  0.7  8.1  16
  2,4,6-TBP  5.6 ± 1.3  5.1  5.7  0.8 ± 0.3  0.6  12  4.6 ± 1.1  3.0  5.9  1.1
  4’-HO-BDE-17  ND  ND  ND  ND  ND  ND  ND  ND  ND  3.5
  2’-HO-BDE-28  ND  ND  ND  ND  ND  ND  ND  ND  ND  2.3
  4-HO-BDE-42  0.9 ± 0.3  ND  0.9  ND  ND  ND  0.9 ± 0.3  ND  1.1  38
  3-HO-BDE-47  1.6 ± 1.1  0.4  1.7  0.1 ± 0.02  0.09  1.3  1.3 ± 0.8  0.3  1.6  11
  5-HO-BDE-47  28 ± 16  5.7  29  1.6 ± 0.5  1.4  23  23 ± 13  4.2  29  ND
  6-HO-BDE-47  9.9 ± 4.9  1.0  10  0.3 ± 0.1  0.2  3.9  7.9 ± 4.0  0.8  10  4.6
  4’-HO-BDE-49  0.9 ± 0.2  ND  0.9  0.3 ± 0.06  0.3  3.5  0.7 ± 0.2  ND  0.8  8.7
  5’-HO-BDE-99  22 ± 15  4.3  23  2.0 ± 0.6  1.7  28  18 ± 12  3.1  23  ND
  6’-HO-BDE-99  1.9 ± 1.0  0.6  1.9  0.3 ± 0.04  0.3  3.7  1.5 ± 0.8  0.4  1.9  ND
  Total  97 ± 55  22    7.0 ± 1.7  6.3    79 ± 44  19
ND, not detected.
aData from Qiu et al. (2007).
Figure 1. Congener profiles of PBDEs (percent of 
the total measured PBDEs) in human blood samples 
(mean ± SE, n = 20) and in a commercial penta-BDE 
product (DE-71).
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cytochrome P450 enzymes. These metabo­
lites are 3­HO­BDE­47, 5­HO­BDE­47, 
6­HO­BDE­47,  4­HO­BDE­42, 
4´­HO­BDE­49, and 2´­HO­BDE­66, the 
structures of which are shown in Figure 3. 
Note that the last three metabolites require a 
bromine shift via an arene oxide during the 
hydroxylation process.
In our previous study on mice, which were 
dosed with DE­71 at 45 mg/kg, 4­HO­BDE­42 
was the most dominant metabolite of BDE­
47 and accounted for 56% of the total 
HO­tetra­BDEs in mouse plasma, followed by 
3­HO­BDE­47 (16%) and 4´­HO­BDE­49 
(13%) (Qiu et al. 2007). The metabolite pro­
file is very different in the human blood sam­
ples studied here. Although 4´­HO­BDE­49 
and  4­HO­BDE­42  were  detected  in 
some of the 20 human blood samples, two 
metabolites formed without a bromine shift 
(5­HO­BDE­47 and 6­HO­BDE­47) were 
more abundant, especially 5­HO­BDE­47, 
which was not even detected in mice 
exposed to high doses of DE­71 (Qiu et al. 
2007). As shown in Table 1 and in Figure 3, 
5­HO­BDE­47 was the most abundant 
HO­tetra­BDE, followed by 6­HO­BDE­47. 
These two metabolites were detected in all 
20 samples and accounted for 90% of the 
total HO­tetra­BDEs. 2´­HO­BDE­66 was 
not detected; 3­HO­BDE­47, 4´­HO­BDE­49 
and 4­HO­BDE­42 were detected in some of 
the samples but at much lower concentrations.
The difference in the metabolic profile 
between humans and mice may be the result 
of species differences in cytochrome P450 
enzyme expression. The superfamily of P450 
has many subfamilies based on amino acid 
sequence identities (Nelson et al. 1993), and 
each different subfamily of P450 has a differ­
ent selectivity in oxidation of the halogenated 
phenyl ring (Bogaards et al. 1995). Results of 
our study of PBDE metabolites in mice sug­
gest that oxidative debromination occurred, 
and this accounts for the production of several 
para­hydroxylated metabolites from BDE­47 
(Qiu et al. 2007). The complex chemical 
reactions involved in oxidative dehalogena­
tion (Isin and Guengerich 2007) are likely to 
require specific CYP enzymes. Although the 
precise set of CYP enzymes involved in oxida­
tive dehalogenation in mammals is unknown, 
the lack of para­hydroxylated metabolites 
in human serum is likely due to the differ­
ent subfamily profiles in mice and humans 
(Bogaards et al. 2000). The para­hydroxylated 
metabolites are likely to behave as endocrine 
disruptors (Hamers et al. 2008; Meerts et al. 
2000; Mercado­Feliciano and Bigsby 2008a), 
and therefore the lack of these in humans may 
explain the lack of any correlation between 
PBDE and thyroid hormone concentrations 
in blood of mothers and their babies (Mazdai 
et al. 2003). However, the enzyme profiles of 
the placenta and fetal liver change through­
out the course of pregnancy (Hakkola et al. 
1998), and there may be transient differences 
in the PBDE metabolite profiles as a result. 
Furthermore, placental CYP1A1 is highly 
inducible by cigarette smoke (Hakkola et al. 
1998). The potential for transient differences 
Qiu et al.
Figure 3. Proposed hydroxylation pathway of BDE-47 in humans and the percentage of metabolites (mean) 
in blood samples measured in this study. ND, not detected.
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(B) a polar column (SP-2331; 30 m). The identified 
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4-HO-13C12-PCB-187 are not shown. 
19 20 21 22
22 24 26 28 30 32 34
Time (min)
a
b
c
d
e
f
IS
a
b d
c
e
f
A
B
Time (min)Metabolites of polybrominated diphenyl ethers in human blood
Environmental Health Perspectives  •  v o l u m e  117 | n u m b e r  1 | January 2009  97
in PBDE metabolite profiles during the course 
of pregnancy and for a correlation between 
exposure to tobacco smoke and metabolism 
require further study.
Some HO­PBDEs are more toxic because 
of the specific position of hydroxyl group; for 
example, 4­HO­BDE­42, 4´­HO­BDE­49, 
and 3­HO­BDE­47 were shown to have 
about four times stronger affinity to trans­
thyretin than thyroxin (Hamers et al. 2008). 
Our data indicate that human P450 enzymes 
do not produce many of these toxic isomers. 
However, 5­HO­BDE­47 has a three times 
stronger affinity to trans  thyretin than thy­
roxin (Hamers et al. 2008). Given the con­
centration of 8.7 nM free thyroxin in serum 
during pregnancy reported by Sterling and 
Hegedus (1962) (compared with the aver­
age concentration of 5­HO­BDE­47 of 
0.1 nmol/kg plasma, with the highest con­
centration being 1.2 nmol/kg plasma in the 
present study), these metabolites, especially 
5­HO­BDE­47, might have substantial 
human effects because of their relatively high 
concentrations in blood.
BDE­99 is the most abundant congener 
of DE­71; however, as discussed above, con­
centrations of BDE­99 were lower than that of 
BDE­47 in human blood in this and in most 
other studies, perhaps because BDE­99 was con­
verted to hydroxylated PBDEs. Like the metab­
olite pattern of BDE­47, 5´­HO­BDE­99 was 
the most abundant hydroxylated metabolite of 
BDE­99, followed by 6´­HO­BDE­99 (Table 
1 and Figure 2). The ratio of 5´­HO­BDE­99 
+ 6´­HO­BDE­99 to 5­HO­BDE­47 + 
6­HO­BDE­47 was 0.84 on average (range, 
0.24–3.2), which was significantly higher than 
the ratio of BDE­99 to BDE­47 (0.39 on aver­
age; range, 0.17–0.69; p < 0.01, t­test). Given 
the symmetrical structure of BDE­47, it has 
a higher probability to form 5­HO­BDE­47 
and 6­HO­BDE­47 than BDE­99 has to form 
5´­HO­BDE­99 and 6´­HO­BDE­99. Thus, 
we conclude that BDE­99 was more likely than 
BDE­47 to be hydroxylated. This may also 
explain why the concentration of BDE­99 was 
usually lower than that of BDE­47 in human 
blood, although it was more abundant in the 
commercial penta­BDE mixtures.
As discussed above, in human blood 
BDE­47 and BDE­99 have similar meta­
bolic profiles, and hydroxylation mainly 
occurs on the phenyl ring with two bromines. 
This process resulted in 5­HO­BDE­47 and 
5´­HO­BDE­99 as the two most abundant 
metabolites of BDE­47 and BDE­99, respec­
tively. If this process were true for BDE­100, 
we might expect that 5´­HO­BDE­100 should 
be the most important hydroxylated metabolite 
of BDE­100; however, 5´­HO­BDE­100 was 
not detected in this study. In fact, there were 
no other large GC peaks on either column in 
the retention time regions where hydroxylated 
penta­BDEs might be expected to elute (Figure 
2). The lack of detection of 5´­HO­BDE­100 
suggests that BDE­100 is more resistant to 
hydroxylation than is BDE­99, explaining the 
increasing ratio of BDE­100 to BDE­99 from 
commercial DE­71 (0.21) to human blood 
(0.59) (Figure 1).
In the present study, we did not 
detect 5´­HO­BDE­100 or several other 
HO­penta­BDEs, including 4­HO­BDE­90, 
4´­HO­BDE­101, and 4´­HO­BDE­103. 
Theoretically, these para­HO­penta­BDEs 
could be formed from BDE­99 or BDE­100 
via hydroxylation with a bromine shift; appar­
ently however, this bromine shift was not 
caused by human P450 enzymes. We should 
note that 4­HO­BDE­90 has the same reten­
tion time as 5´­HO­BDE­99 on non  polar GC 
columns (such as Rxi­5 and DB­5); however, 
on polar columns (such as SP­2331) these 
two compounds can easily be distinguished. 
In another study, Athanasiadou et al. (2008) 
quantified this peak relative to 4­HO­BDE­90 
with a DB­5 column.
Bromophenols. In our previous study of 
mice (Qiu et al. 2007), three bromo  phenols 
were identified in blood samples after expo­
sure to DE­71. These bromophenols were 
also detected in human blood samples. To 
our knowledge, 2,4,5­TBP is not a commer­
cial product, thus the presence of 2,4,5­TBP 
in human blood (at 6.4 ng/g lipid) indi­
cates that the diphenyl ether bond of some 
PBDE congeners (BDE­99 for example) can 
be cleaved. For 2,4­DBP and 2,4,6­TBP, 
although they were also detected in blanks 
in this and in other studies (Thomsen et al. 
2001), the concentrations of these two 
compounds in the blood samples (averag­
ing 16 and 4.6 ng/g lipid for 2,4­DBP and 
2,4,6­TBP, respectively) were > 10­fold 
higher than those meas  ured in the blanks, 
indicating that these two bromophenols came 
from sources other than the laboratory blank. 
One source of these two contaminants might 
be exposure to these chemicals because both 
2,4­DBP and 2,4,6­TBP have been used as 
flame retardants (World Health Organization 
1997). Another source, such as 2,4,5­TBP, 
might be cleavage of the diphenyl ether bond 
of PBDEs. Based on the proposed metabolic 
pathway for mice (Qiu et al. 2007), 2,4­DBP 
could be a metabo  lite of BDE­47, and 
2,4,6­TBP could be a metabolite of BDE­100 
and BDE­154.
The average total concentration of 
the three bromophenols was 27 ng/g lipid 
(range, 1.2–310 ng/g lipid). For comparison, 
the average total concentration of the mea­
sured HO­PBDEs was 52 ng/g lipid (range, 
0.8–590 ng/g lipid). Thus, although the bro­
mophenols might have other sources, the 
concentrations of bromophenols were com­
parable to those of HO­PBDEs, suggesting 
that cleavage of the diphenyl ether bond was 
an important metabolic pathway for PBDEs 
in humans.
Summary
Unlike the metabolites measured in mice 
after dosing with PBDE, the HO­PBDE 
metabolites of BDE­47 in humans without a 
bromine shift were abundant. Two metabo­
lites, 5­HO­BDE­47 and 6­HO­BDE­47, 
accounted for 90% of the total HO­tetra­
BDE concentration in our subjects. 
5´­HO­BDE­99 and 6´­HO­BDE­99 were 
the most abundant metabolites of BDE­99 
in our subjects. The relative concentrations 
between precursor and the corresponding 
HO­PBDE indicated that BDE­99 was more 
likely to be hydroxylated than BDE­47 and 
BDE­100, and this observation may explain 
the different congener profiles noticed for 
PBDEs in human blood as opposed to the 
commercial penta­BDE mixture. In addition 
to HO­PBDEs, three bromophenols were also 
detected in human blood, indicating the cleav­
age of the diphenyl ether bond of PBDEs. 
The total concentrations of the hydroxylated 
metabolites (HO­PBDEs and bromophenols) 
were close to those of the PBDEs, suggesting 
that these hydroxylated metabolites may be 
accumulating in human blood.
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